PofoliaShared via Pofolia

Journal of the American College of Cardiology· 2026Q1

Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure

Ross T. Campbell, Joanna Osmanska, Kieran F. Docherty, Fozia Zahir Ahmed et al.

Short summary

An early discharge strategy using a wearable subcutaneous furosemide minipump increased days alive and out of hospital (DAOH) by 4.0 days at 30 days compared to usual care (n=172).

AI-generated from the title and abstract; the full text is not read.

Key points

  • Early discharge with subcutaneous furosemide minipump increased DAOH by 4.0 days at 30 days (P < 0.001).
  • Index hospitalization was reduced by a mean of 5.5 days (P < 0.001).
  • The DAOH benefit persisted at 60 days, despite a higher rate of heart failure readmissions in the early discharge group.
  • 3% of minipump placements had device-related problems, none serious.

AI-generated from the title and abstract; the full text is not read.

Abstract

BackgroundPatients hospitalized for heart failure often require prolonged intravenous diuretic therapy, contributing to costs and risks associated with inpatient care. ObjectivesWe evaluated whether an early discharge strategy using subcutaneous furosemide delivered via a wearable minipump could increase days alive and out of hospital (DAOH). MethodsIn this multicenter, open-label, randomized, active-controlled trial in the United Kingdom, 172 patients hospitalized for heart failure requiring ongoing parenteral diuretics were randomly assigned to an early discharge strategy or usual care. Patients in the early discharge group received pH-neutral subcutaneous furosemide via a wearable, patient-operated minipump; postdischarge care included a review every 3 days while receiving subcutaneous furosemide. Both groups had a 2-week clinic review. The primary outcome was DAOH at 30 days after randomization. ResultsA total of 92 patients were assigned to early discharge and 80 to usual care. The early discharge strategy resulted in 4.0 more DAOH at 30 days (95% CI: 2.1-5.8 days; P < 0.001). Index hospitalization was shorter by a mean of 5.5 days (95% CI: 7.4-3.6 days; P < 0.001). The benefit in DAOH was sustained at 60 days (difference 4.2 days; 95% CI: 0.9-7.6 days), despite more heart failure readmissions in the early discharge group (13 [14%] patients vs 5 [6%] patients; OR: 2.45; 95% CI: 0.81-7.43). Serious adverse events occurred in 25% and 23% of patients, respectively. Device-related problems occurred with 3% of minipump placements, but none were serious. ConclusionsAn early discharge strategy using a subcutaneous furosemide minipump increased DAOH compared with usual care. (Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure [SUBCUT-HF II]; NCT05419115).

The authors' abstract, as published at the source. Journal of the American College of Cardiology, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Cardiology and Cardiovascular Medicine

Cardiology and Cardiovascular MedicineMedicine